Evidence map›Paper›PMID 37243163›Full record

ArticleViruses2023

A Recombinant Chimeric Cedar Virus-Based Surrogate Neutralization Assay Platform for Pathogenic Henipaviruses.

Moushimi Amaya, Randy Yin, Lianying Yan, Viktoriya Borisevich, Bishwo N Adhikari, Andrew Bennett, Francisco Malagon, Regina Z Cer, Kimberly A Bishop-Lilly, Antony S Dimitrov and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Viruses, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. AnFrontiers in chemical biology · 2024
    Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 1 country.

Moushimi AmayaDepartment of Microbiology and Immunology, Uniformed Services University, Bethesda, MD 20814, USA.
Randy YinDepartment of Microbiology and Immunology, Uniformed Services University, Bethesda, MD 20814, USA.
Lianying YanDepartment of Microbiology and Immunology, Uniformed Services University, Bethesda, MD 20814, USA.
Viktoriya BorisevichDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA.
Bishwo N AdhikariGenomics and Bioinformatics Department, Biological Defense Research Directorate, Naval Medical Research Command-Frederick, Fort Detrick, Frederick, MD 21702, USA.ORCID 0000-0003-4840-9609
Andrew BennettDefense Threat Reduction Agency, Fort Belvoir, VA 22060, USA.
Francisco MalagonDefense Threat Reduction Agency, Fort Belvoir, VA 22060, USA.
Regina Z CerGenomics and Bioinformatics Department, Biological Defense Research Directorate, Naval Medical Research Command-Frederick, Fort Detrick, Frederick, MD 21702, USA.
Kimberly A Bishop-LillyGenomics and Bioinformatics Department, Biological Defense Research Directorate, Naval Medical Research Command-Frederick, Fort Detrick, Frederick, MD 21702, USA.ORCID 0000-0002-5744-8493
Antony S DimitrovDepartment of Microbiology and Immunology, Uniformed Services University, Bethesda, MD 20814, USA.ORCID 0000-0001-8356-6701
Robert W CrossDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA.
Thomas W GeisbertDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA.ORCID 0000-0003-0858-1877
Christopher C BroderDepartment of Microbiology and Immunology, Uniformed Services University, Bethesda, MD 20814, USA.ORCID 0000-0001-5382-0510
Henry M. Jackson Foundation · USThe University of Texas Medical Branch at Galveston · USLeidos (United States) · USUniformed Services University of the Health Sciences · USUnited States Army Medical Research and Development Command · USDefense Threat Reduction Agency · US

Funding

Regulatory Compliance Core - Galveston National Laboratory BSL4 OperationsUC7AI094660 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI Gene Garrard Olinger · 2011 to 2026
$208.8M
Project 3 - USUHSU19AI142764 · NIAID · HENRY M. JACKSON FDN FOR THE ADV MIL/MED · PI BRODER, CHRISTOPHER C · 2019 to 2023
$24.6M
National Institute of Allergy and Infectious Diseases U19AI142764National Institute of Allergy and Infectious Diseases UC7AI094660NIAID NIH HHS U19 AI142764NIAID NIH HHS UC7 AI094660
6 · The paper itself

Abstract

The henipaviruses, Nipah virus (NiV), and Hendra virus (HeV) can cause fatal diseases in humans and animals, whereas Cedar virus is a nonpathogenic henipavirus. Here, using a recombinant Cedar virus (rCedV) reverse genetics platform, the fusion (F) and attachment (G) glycoprotein genes of rCedV were replaced with those of NiV-Bangladesh (NiV-B) or HeV, generating replication-competent chimeric viruses (rCedV-NiV-B and rCedV-HeV), both with and without green fluorescent protein (GFP) or luciferase protein genes. The rCedV chimeras induced a Type I interferon response and utilized only ephrin-B2 and ephrin-B3 as entry receptors compared to rCedV. The neutralizing potencies of well-characterized cross-reactive NiV/HeV F and G specific monoclonal antibodies against rCedV-NiV-B-GFP and rCedV-HeV-GFP highly correlated with measurements obtained using authentic NiV-B and HeV when tested in parallel by plaque reduction neutralization tests (PRNT). A rapid, high-throughput, and quantitative fluorescence reduction neutralization test (FRNT) using the GFP-encoding chimeras was established, and monoclonal antibody neutralization data derived by FRNT highly correlated with data derived by PRNT. The FRNT assay could also measure serum neutralization titers from henipavirus G glycoprotein immunized animals. These rCedV chimeras are an authentic henipavirus-based surrogate neutralization assay that is rapid, cost-effective, and can be utilized outside high containment.

Indexed as

Hendra VirusHenipavirus InfectionsNipah VirusAnimalsGlycoproteinsGreen Fluorescent ProteinsHenipavirusHumansViral Envelope ProteinsGlycoproteinsGreen Fluorescent ProteinsViral Envelope ProteinsantibodyCedar viruschimeraHendra virushenipavirusNipah virusreverse geneticsserumvaccinevirus-host cell interactionvirus neutralization

Identifiers

PMID37243163
PMCPMC10223282
OpenAlexW4367315016

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.